Kura Oncology vs Nurix Therapeutics
Nurix Therapeutics reported revenue of $84 million in fiscal 2025, 1.2 times Kura Oncology's $68 million in fiscal 2025. Kura Oncology's revenue grew 25.2% in its latest year, and Nurix Therapeutics' grew 54.0%. Kura Oncology had an operating margin of -449.9%, against -340.2% at Nurix Therapeutics. Free cash flow was −$71 million at Kura Oncology and −$263 million at Nurix Therapeutics. Their fiscal years end in different months (December 31 and November 30), so the periods don't line up exactly.
Side by side
| Kura Oncology | Nurix Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Nov 30, 2025 |
| Revenue | $68M | $84M |
| Revenue growth | 25.2% | 54.0% |
| Revenue growth a year, last 5 years | — | 36.4% |
| Gross margin | — | — |
| Operating margin | −449.9% | −340.2% |
| Net margin | −412.9% | −314.9% |
| Free cash flow | −$71M | −$263M |
| Free cash flow margin | −104.8% | −313.7% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.8% | 29.1% |
| Last close | $7.77 | $15.48 |
| P/E at the last close | — | 6.7× |
| Insider trades, last 12 months | — | sold $4.2 million |
| Piotroski F-score | 3 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Kura OncologyNurix Therapeutics
Operating margin
Percent of revenue
Kura OncologyNurix Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Kura OncologyNurix Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Kura Oncology and Nurix Therapeutics pages.